TSBX Turnstone Biologics Corp. Company Short-Term Debt

Turnstone Biologics (TSBX) develops personalized vaccines and TIL-based therapies, leveraging patent protection and FDA data. The business expands through partnerships with scientific centers to develop immunotherapy. High R&D costs and strict regulatory oversight create significant barriers to entry for competitors. This price chart confirms these data, with the indicator standing at 0.00.

TSBX Turnstone Biologics Corporation Short-Term Debt (02/21/2024 - 08/24/2025)

Analytical breakdowns and data insights for company Turnstone Biologics Corp (TSBX)

- current quotes and average value forecast:
Price Chart Turnstone Biologics Corporation|TSBX - Average Forecast Price
- market capitalization data:
Market Value Turnstone Biologics Corp.|TSBX - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Turnstone Biologics|TSBX - Total Stockholders' Equity|Market Capitalization to Book Value Ratio turnstonebio.com|TSBX - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Turnstone Biologics|TSBX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Turnstone Biologics Corporation|TSBX - Aggregate Debt Obligations|Debts to Book Capitalization Turnstone Biologics Corp.|TSBX - Long-Term Debt Volume|Company Short-Term Debt Turnstone Biologics|Quick Liquidity turnstonebio.com
- earnings and multiples data:
TSBX - Net Income
General company analysis:turnstonebio.com (TSBX)

For Turnstone Biologics (TSBX), whose operations are strictly regulated by FDA standards, liquidity management is critical when financing clinical trials. This short-term debt burden metric aggregates all credit obligations maturing within twelve months, allowing for an assessment of working capital deficit risks. Monitoring this metric helps investors timely identify a dangerous increase in borrowing that could lead to a price collapse during a shift in the market cycle.

Competitors of Turnstone Biologics

IBRX - Company Short-Term Debt|Short-Term Debt Immunocore Holdings|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt Zymeworks Inc.|Short-Term Debt tangotx.com TNGX|Company Short-Term Debts IOVA|Immatics NV (IMTX) - Short-Term Indebtedness|Xencor Corp - Company Current Liabilities|Compass Therapeutics Corp (CMPX) - Short-Term Debt|REPL: Company Current Liabilities|Company Short-Term Loans and Borrowings LYEL (lyell.com)|IPHA: Company Short-Term Debts|PYXS - Short-Term Debt Volume|Company Short-Term Debt Compugen Ltd|Company Current Liabilities IO Biotech Inc. (IOBT)|Company Short-Term Debt Sutro Biopharma, Inc. (STRO)|Company Current Liabilities minktherapeutics.com INKT|Werewolf Therapeutics, Inc. - Company Current Liabilities|Company Short-Term Debts Immix Biopharma Inc. IMMX|ALXO - Company Short-Term Debt|CUE (Cue Biopharma Inc.) - Company Short-Term Indebtedness|pdsbiotech.com (PDSB) - Company Short-Term Debt|Short-Term Debt Sonnet BioTherapeutics Holdings (SONN)|Company Current Liabilities MAIA|LIMN - Short-Term Indebtedness|Company Current Liabilities LVTX (LAVA Therapeutics N.V.)|Amount of Current Liabilities NXTC|Company Short-Term Debts LPTX (Leap Therapeutics)|Company Short-Term Loans and Borrowings INTS|Sensei Bio - Company Short-Term Debts|Short-Term Debt Theriva Biologics Inc|gritstonebio.com (GRTS) - Company Short-Term Debt|Kineta Corp - Company Short-Term Loans and Borrowings|NEXI (NexImmune, Inc.) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)